| human | Q5 |
| P735 | given name | Ulrike | Q18924997 |
| Ulrike | Q18924997 | ||
| P106 | occupation | researcher | Q1650915 |
| Q38462515 | A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia |
| Q54597208 | A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia. |
| Q38781933 | A transplant "immunome" screening platform defines a targetable epitope fingerprint of multiple myeloma |
| Q54592072 | Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22). |
| Q44933471 | Allogeneic hematopoietic stem cell transplantation: an option for long-term survival for patients with simultaneous appearance of myeloid and lymphatic malignancies |
| Q37559330 | Allogeneic stem cell transplantation in acute myeloid leukemia: establishment of indications on the basis of individual risk stratification |
| Q37083601 | Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation |
| Q33756719 | Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival |
| Q53286367 | Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype. |
| Q42979550 | Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML. |
| Q41236177 | Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation |
| Q48666333 | Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis |
| Q58716610 | Autologous Transplantation for Older Adults with AML |
| Q33878649 | B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia |
| Q53362128 | Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia. |
| Q54730665 | Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis. |
| Q35018518 | CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia |
| Q37853793 | Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors |
| Q58695596 | Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use |
| Q46047569 | Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation |
| Q43199531 | Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis |
| Q46373564 | Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens |
| Q51541686 | Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia. |
| Q35596919 | Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA |
| Q49362075 | Coincidence of 5q deletion and the JAK2V617F mutation: report of two patients with overlapping myelodysplastic and myeloproliferative features and review of the literature |
| Q43014294 | Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML. |
| Q35193722 | Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells |
| Q36410168 | Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? |
| Q33649332 | Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease |
| Q51978963 | Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. |
| Q37594993 | Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML). |
| Q37432236 | Current status of gene expression profiling in the diagnosis and management of acute leukaemia |
| Q45385855 | Cyclin D1 (CCND1) messenger RNA expression as assessed by real-time PCR contributes to diagnosis and follow-up control in patients with mantle cell lymphoma |
| Q45356647 | Cyclosporine area under the curve after allogeneic hematopoietic stem cell transplantation is an indicator of Epstein-Barr virus DNAemia |
| Q53259347 | Cytogenetic methods in chronic lymphocytic leukemia. |
| Q39002065 | Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis |
| Q52668587 | Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders. |
| Q37112871 | Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera |
| Q51553890 | Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia. |
| Q54324358 | Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia. |
| Q46148715 | Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib |
| Q43005378 | Diagnosis of Toxoplasma gondii infection after allogeneic stem cell transplant can be difficult and requires intensive scrutiny |
| Q36765475 | Diagnostic pathways in acute leukemias: a proposal for a multimodal approach |
| Q37669460 | Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes |
| Q37391398 | Discussion of the applicability of microarrays: profiling of leukemias |
| Q47883105 | Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category |
| Q34295164 | Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data |
| Q45126468 | Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting |
| Q57740679 | EZH2 mutations and their association with PICALM-MLLT10 positive acute leukaemia |
| Q54595113 | Flow cytometric identification of 76 patients with biclonal disease among 5523 patients with chronic lymphocytic leukaemia (B-CLL) and its genetic characterization. |
| Q54545270 | Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia. |
| Q40555529 | Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group |
| Q54646223 | Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients. |
| Q38473283 | Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders |
| Q37767035 | Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies |
| Q37584250 | Gene expression profiling in acute myeloid leukaemia (AML). |
| Q51769718 | HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen. |
| Q43111723 | Immunohistochemistry and molecular analyses in myeloid sarcoma of the breast in a patient with relapse of NPM1-mutated and FLT3-mutated AML after allogeneic stem cell transplantation |
| Q45260013 | Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma |
| Q27824859 | Implications of NRAS mutations in AML: a study of 2502 patients |
| Q52730276 | In Situ Validation of the Endothelial Cell Receptor GRP78 in a Case of Rhinocerebral Mucormycosis. |
| Q36719203 | Insight into the molecular pathogenesis of myeloid malignancies |
| Q40077590 | Intestinal Pneumatosis Associated with Tuberculosis after Allogeneic Hematopoietic Stem Cell Transplantation |
| Q51811978 | JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. |
| Q55291531 | Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia. |
| Q42370328 | Modifying therapy in patients with advanced Hodgkin's lymphoma by integrating early metabolic response by interim PET-CT. |
| Q36366973 | Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow |
| Q35007333 | Molecular diagnostics in acute leukemias |
| Q39112294 | Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia |
| Q37784131 | Molecular genetics in acute myeloid leukemia |
| Q37973867 | Monitoring and prevention of relapse after allogeneic hematopoietic cell transplantation for myeloid malignancies |
| Q51351304 | Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. |
| Q54270410 | Multiparameter Flow Cytometry Provides Independent Prognostic Information in Patients with Suspected Myelodysplastic Syndromes: A Study on 804 Patients. |
| Q38216554 | Multiparameter flow cytometry in the differential diagnosis of aberrant T-cell clones of unclear significance |
| Q41592685 | Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: A study on 804 patients |
| Q44601971 | Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms |
| Q38346888 | Mutational profiling in patients with MDS: ready for every-day use in the clinic? |
| Q37701292 | Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies |
| Q36266642 | Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges |
| Q37332638 | Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing |
| Q43014298 | NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following All |
| Q42967538 | NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following all |
| Q30370038 | Older patients with myeloma derive similar benefit from autologous transplantation. |
| Q53164083 | Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib. |
| Q30252975 | Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes |
| Q36928803 | Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis |
| Q43449321 | Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups |
| Q33383573 | Pegfilgrastim compared to lenograstim after allogeneic peripheral blood stem-cell transplantation from unrelated donors |
| Q38857091 | Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial |
| Q38154339 | Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing |
| Q37497800 | Perspectives of gene expression profiling for diagnosis and therapy in haematological malignancies |
| Q58793853 | Pitfalls in the molecular follow up of mutant acute myeloid leukemia |
| Q45987373 | Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. |
| Q41554713 | Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria |
| Q27851417 | Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients |
| Q44594955 | Quantification of rare NPM1 mutation subtypes by digital PCR. |
| Q54501898 | Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. |
| Q45923084 | RQ-PCR based WT1 expression in comparison to BCR-ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib-treated chronic myeloid leukaemia. |
| Q35565387 | Rare cytogenetic abnormalities in myelodysplastic syndromes |
| Q28307278 | Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia |
| Q38199623 | Relapse assessment following allogeneic SCT in patients with MDS and AML. |
| Q53136705 | Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. |
| Q37510948 | Safety of conditioning agents for allogeneic haematopoietic transplantation |
| Q45869898 | Second allogeneic stem cell transplantation in myeloid malignancies |
| Q30317754 | Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change |
| Q45929142 | Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. |
| Q43209094 | Severe aplastic anaemia following leflunomide therapy |
| Q54616756 | Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations. |
| Q34240314 | The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients |
| Q36662009 | The benefit of population-based studies for older patients with acute myeloid leukemia |
| Q51130292 | The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia--a report from the German Registry covering the period from 1998 to 2004. |
| Q24675681 | The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers |
| Q51815750 | The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes. |
| Q37812865 | The role of multiparameter flow cytometry for disease monitoring in AML. |
| Q46741920 | Unusual course of myelodysplastic syndrome with presumed familial origin |
| Q36936505 | Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases |
| Q53739684 | [Microarrays and gene expression profiling for the diagnosis in leukemia. From research studies to routine application]. |
Search more.